Abstract
Portal hypertension is the most important complication that develops in patients with cirrhosis. Several studies have shown that angiogenesis (i.e. splanchnic neovascularization) driven by VEGF and other proangiogenic molecules, like PDGF, may be a major mechanism involved in portal hypertension, hyperdynamic splanchnic circulation and portosystemic collateralization. According with this, antiangiogenic therapies, like sorafenib or sunitinib, have been recently shown to reduce portosystemic collateral circulation, improve splanchnic hyperdynamics and decrease portal pressure in experimental model of portal hypertension. This effect was associated to a decrease in VEGF, PDGF expression and splanchnic neovascularization. In addition, these therapies were associated with a decrease in both splanchnic and intrahepatic inflammatory infiltrates, in hepatic stellate cell activation and in intrahepatic fibrosis. These data suggest that antiangiogenic therapies may therefore, by limiting liver fibrosis and inflammation in cirrhosis, prevent the occurrence of severe complications, such as portal hypertension and potentially liver cancer.
References
May 1, 1991·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·J HaratakeA Horie
Dec 1, 1982·The Journal of Clinical Investigation·P M HuetJ O Lough
Oct 1, 1993·The Journal of Clinical Investigation·D C RockeyS L Friedman
Oct 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·C HoussetD M Bissell
Jul 11, 1997·Science·P LindahlC Betsholtz
Feb 14, 1998·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·D C RockeyC Housset
Oct 9, 1999·The American Journal of Pathology·O RosmorducR Poupon
May 1, 2002·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Christophe CorpechotOlivier Rosmorduc
Jun 5, 2003·Nature Medicine·Peter Carmeliet
Dec 17, 2004·Cellular Signalling·B MasriY Audigier
May 17, 2005·Journal of Hepatology·Mercedes FernandezJaime Bosch
Oct 16, 2007·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Sònia TuguesManuel Morales-Ruiz
Dec 6, 2007·Journal of Clinical Gastroenterology·Vijay Shah
Jan 16, 2008·Journal of Cellular and Molecular Medicine·Marc MejiasMercedes Fernandez
Jan 18, 2008·The EMBO Journal·Hiroyasu KidoyaNobuyuki Takakura
Jul 25, 2008·The New England Journal of Medicine·Josep M LlovetUNKNOWN SHARP Investigators Study Group
Sep 26, 2008·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Alessandro PrincipeWladimiro Jiménez
Dec 17, 2008·Journal of Hepatology·Carolina TianiMercedes Fernandez
Jan 13, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Marc MejiasMercedes Fernandez
Sep 3, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Eleonora PatsenkerDetlef Schuppan
Sep 4, 2009·Journal of Hepatology·Thomas ReibergerMarkus Peck-Radosavljevic
Citations
Feb 23, 2011·PloS One·Romain CoriatFrançois Goldwasser
Feb 3, 2016·Frontiers in Pharmacology·Kai QuChang Liu
Aug 29, 2012·Evidence-based Complementary and Alternative Medicine : ECAM·Jing LvChenghai Liu
Apr 1, 2014·Gastroenterology·John P Iredale, Ramon Bataller
Sep 3, 2016·Oncotarget·Kai QuChang Liu
Oct 1, 2013·Hepatology International·Savneet Kaur, K Anita
Mar 26, 2013·Molecular Medicine Reports·Jingjing WangBo Han
Sep 11, 2018·World Journal of Gastroenterology : WJG·Dmitry Victorovich GarbuzenkoEvgeniy Leonidovich Kazachkov